A study reveals alarming rates of antibiotic resistance in Gram-negative bacteria, highlighting the urgent need for ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Addresses the significant threat of antimicrobial resistance.

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESSWIRE / 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whol ...

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...